DCM
CORZ icon

Dilation Capital Management’s Core Scientific CORZ Stock Holding History

Dilation Capital Management’s Portfolio CORZ Stock Details CORZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,490
Closed -$1.2M – 16
2024
Q4 		$1.2M Buy
+85,490
New +$1.26M 1.11% 20

Other funds holding CORZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
GC
Gullane Capital Memphis, Tennessee $37.4M AUM 112.18% 1-Year Est. Return
OWP
ORG Wealth Partners Dallas, Texas $508M AUM 83.62% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
JCM
JAT Capital Management Greenwich, Connecticut $59.3M AUM 134.04% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return

Dilation Capital Management's CORZ Position: Q1 2025 in Review

Dilation Capital Management sold out of Core Scientific (CORZ) in Q1 2025, closing a stake of 85,490 shares — an estimated $1.2M sold.

Dilation Capital Management first reported a position in CORZ in Q4 2024 and held it in 1 quarter. The position peaked at $1.2M in Q4 2024. 336 funds tracked by Wall St. Rank hold CORZ as of Q1 2025.

  • Dilation Capital Management reported no remaining Core Scientific position as of Q1 2025 after selling out during the quarter.
  • Dilation Capital Management sold 85,490 Core Scientific shares in Q1 2025, an estimated $1.2M.
  • Dilation Capital Management first reported a position in Core Scientific in Q4 2024 and held it in 1 quarter.
  • Dilation Capital Management's Core Scientific position peaked at $1.2M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Core Scientific as of Q1 2025.

Based on Dilation Capital Management's 13F filing for Q1 2025, filed 14 May 2025.